From Nasdaq: 2025-05-06 12:32:00

Eli Lilly and Company (NYSE: LLY) experienced a significant drop in shares after reporting Q1 earnings, with a 12% decline in one day. CVS Health (NYSE: CVS) announced a key partnership with Novo Nordisk, intensifying competition in the weight-loss drug market.

Despite an earnings miss due to a one-time charge, Lilly’s business remains strong, with revenues up 45%. The partnership between CVS and Novo Nordisk dealt a blow to Lilly, impacting its weight loss treatment Zepbound.

The deal could impact smaller companies more, as they are less likely to cover weight loss drugs. Lilly still dominates the weight loss drug market with Zepbound, holding a 53% share. The company is also developing a next-generation oral GLP-1, demonstrating scientific prowess. Overall, Eli Lilly stock remains a good investment. Eli Lilly and Company, listed on the NYSE under LLY, reported strong financial results for the third quarter of 2021. The pharmaceutical giant saw a revenue increase of 5% to $6.01 billion, driven by the growth of key products like Trulicity and Taltz. Net income also rose to $1.8 billion.



Read more at Nasdaq:: Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?